Plebiotic 

Non acquired resistance novel cancer drugs based on proprietary Molecular Dynamics simulation

OWNER

Álvaro López-Medrano (See Profile)

Sector

Cancer therapeutics

Stage

Prototyping, preclinical

Country

Spain


Proprietary (US9727690B2) Molecular Dynamics (MD) to solve the problem of acquired resistance in cancer treatments

Novel Non-smal Cell Lung Cancer (NSCLC) drugs with antiproliferative effects and no acquired resistance (in-vitro test)

The investment is sought to obtain First-In-Human approval: access the NSCLC market rising from $6B to $27B until 2025

This information is confidential, do not share or copy.

Under evaluation at least till: 23th June

If you want to have more information or you want to review the project, you have to login or register

©2020 BioExpert Network

About cookies

This website uses cookies to give you the best user experience. If you continue browsing you are giving your consent for the acceptance of those cookies and the acceptance of our cookies policy.

If you continue to browse and use this website you are agreeing to comply with and be bound by the following Terms of Use

ACEPTAR
Aviso de cookies

Log in with your credentials

or    

Forgot your details?

Create Account

Skip to toolbar